Japan Cancer Immunotherapy Market Size & Outlook
Japan cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Japan cancer immunotherapy market highlights
- The Japan cancer immunotherapy market generated a revenue of USD 5,275.8 million in 2023 and is expected to reach USD 11,719.5 million by 2030.
- The Japan market is expected to grow at a CAGR of 12.1% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 5,275.8 million |
| Market revenue in 2030 | USD 11,719.5 million |
| Growth rate | 12.1% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Japan accounted for 4.2% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,004.2 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 68.17% in 2023. Horizon Databook has segmented the Japan cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Rapidly aging population in Japan is one of the factors widening the cancer patient pool in the country. The treatment paradigm for cancer in Japan is steadily shifting toward immunotherapeutic options post the development of Opdivo by immunologist Tasuku Honjo, which won him the Nobel Prize in Physiology or Medicine in 2018.
In May 2019, Kyoto University collaborated with Honjo & his team to develop the first cancer immunotherapy research center in Japan. Currently, the three major approaches used in cancer immunotherapy in Japan are adoptive cell transfer therapy, immune checkpoint blockade, and active vaccination.
Technological advancements in the field of medical science is fuelling the growth of cancer immunotherapy market in Japan. For instance, the advent of NGS technology has enabled genetic background of human cancers and identifications of potent neoantigens.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan cancer immunotherapy market size, by product, 2018-2030 (US$M)
Japan Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
